Literature DB >> 23892106

Constitutive excessive erythrocytosis causes inflammation and increased vascular permeability in aged mouse brain.

O O Ogunshola1, M Moransard, M Gassmann.   

Abstract

Excessive erythrocytosis results in severely increased blood viscosity that may compromise the vascular endothelium. Using our transgenic mouse model of excessive erythrocytosis we previously showed that despite altered brain endothelial cell morphology and an activated vasculature, brain vascular integrity was largely maintained up to 4-5 months of age. We now present data showing that persistent long-term damage of the vascular wall during the later stages of adulthood (9-12 months) results in a chronic detrimental inflammatory phenotype and increased vessel permeability that likely contributes to the reduced life span of our erythropoietin overexpressing transgenic mouse. In aged transgenic animals inflammatory cells were detected in brain tissue and elevated RNA and protein levels of inflammatory markers such as IL-6 and TNFα were observed in both brain tissue and blood plasma. Additionally, increased expression of p53 and other pro-apoptotic markers, as well as decreased Bcl-xL expression in the brain vasculature, indicated ongoing cell death within the vascular compartment. Finally, abnormally elevated vascular permeability in all organs was detected in correlation with decreased expression of the tight junction protein occludin and the adherens junction protein β-catenin in brain. Thus chronic erythrocytosis results in sustained activation of inflammatory pathways, vascular dysfunction and blood-brain barrier disruption.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell death; Endothelial activation; Endothelium; Erythropoietin

Mesh:

Substances:

Year:  2013        PMID: 23892106     DOI: 10.1016/j.brainres.2013.07.033

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

Review 1.  Stem cell guidance through the mechanistic target of rapamycin.

Authors:  Kenneth Maiese
Journal:  World J Stem Cells       Date:  2015-08-26       Impact factor: 5.326

Review 2.  Erythropoietin and diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  World J Diabetes       Date:  2015-10-25

3.  Charting a course for erythropoietin in traumatic brain injury.

Authors:  Kenneth Maiese
Journal:  J Transl Sci       Date:  2016-03-26

Review 4.  Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Br J Clin Pharmacol       Date:  2015-12-26       Impact factor: 4.335

5.  COX-2 contributes to LPS-induced Stat3 activation and IL-6 production in microglial cells.

Authors:  Jie Zhu; Shuzhen Li; Yue Zhang; Guixia Ding; Chunhua Zhu; Songming Huang; Aihua Zhang; Zhanjun Jia; Mei Li
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

6.  Regeneration in the nervous system with erythropoietin.

Authors:  Kenneth Maiese
Journal:  Front Biosci (Landmark Ed)       Date:  2016-01

Review 7.  Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease.

Authors:  Kenneth Maiese
Journal:  Neural Regen Res       Date:  2015-04       Impact factor: 5.135

8.  Sirt1 Protects Endothelial Cells against LPS-Induced Barrier Dysfunction.

Authors:  Weijin Zhang; Yaoyuan Zhang; Xiaohua Guo; Zhenhua Zeng; Jie Wu; Yanan Liu; Jing He; Ruiting Wang; Qiaobing Huang; Zhongqing Chen
Journal:  Oxid Med Cell Longev       Date:  2017-10-25       Impact factor: 6.543

9.  Induction of VEGFA and Snail-1 by meningitic Escherichia coli mediates disruption of the blood-brain barrier.

Authors:  Ruicheng Yang; Wentong Liu; Ling Miao; Xiaopei Yang; Jiyang Fu; Beibei Dou; Aoling Cai; Xin Zong; Chen Tan; Huanchun Chen; Xiangru Wang
Journal:  Oncotarget       Date:  2016-09-27

10.  Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms.

Authors:  M Moransard; M Bednar; K Frei; M Gassmann; O O Ogunshola
Journal:  J Neuroinflammation       Date:  2017-10-13       Impact factor: 8.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.